Recruiting
Phase 3

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Sponsor:

Inozyme Pharma

Code:

NCT06046820

Conditions

Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency

Autosomal Recessive Hypophosphatemic Rickets

Generalized Arterial Calcification of Infancy

Eligibility Criteria

Sex: All

Age: 1 - 12

Healthy Volunteers: Not accepted

Interventions

INZ-701

Control Arm (Conventional Therapy)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information